Company Overview
Company Type: Private Company
Website: www.syngpharma.com
Number of Employees: -
Year Founded: 2012
Total Amount Raised (CAD mm)†: -
Total Rounds of Funding**:-
Latest Post-Money Valuation ($ mm) -
Latest Pre-Money Valuation ($ mm) -
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
SYNG Pharmaceuticals Inc. is a pre-clinical stage biotechnology company and develops blood-based in-vitro diagnostic test and non-hormonal therapy for endometriosis. It develops diagnostic and therapeutic against endometriosis. The company develops SP011, a peptide to inhibit a target for its role in the abnormal proliferation of cells. The company develops a biomarker and a non-invasive diagnostic for endometriosis. The company was founded in 2012 and is based in Kingston, Canada.


Financial Information (Currency: CAD, in mm)
Total Revenue
-
Operating Income
-
Total Assets
-
Gross Profit
-
EBITDA
-
Total Debt
-
Net Income
-
Estimated Number of Employees
-
Net Debt
-
* Hover over data point numbers for date and source.

Key Professionals
Name
Title
Singh, Vinay 
Founder & CEO
Hsu, Ted 
Communications Director
Singh, Avinash 
COO of India

Key Board Members
Name
Title
Casper, Robert F.
Chair of Clinical Advisory Board
Tataryn, Ivanna 
Member of Clinical Advisory Board
Young, Steven 
Member of Clinical Advisory Board


Primary Industry Classification
Biotechnology


Primary Office Location
945 Princess Street | Kingston, ON | K7L 3N6 | Canada
Phone: 613-532-9426   

Current and Pending Investors
Investor
Initial Investment Date
Stake Type
Current Stake Amount
Round(s)
VentureHealth
-
Unknown
-
-


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Last 5 Key Developments
Date
Event Type
Headline
Jun-22-2017
Company Conference Presentations
SYNG Pharmaceuticals Inc Presents at BIO International Conference 2017, Jun-22-2017 02:30 PM


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
Infinata, Inc.
Infinata Research
Dec 23, 2019 04:37 AM
SYNG Pharmaceuticals Inc.
Syng Pharmaceuticals Inc. - Company Report
Reports
8
Infinata, Inc.
Infinata Research
Sep 30, 2019 05:37 AM
SYNG Pharmaceuticals Inc.
Syng Pharmaceuticals Inc. - Company Report
Reports
10
Infinata, Inc.
Infinata Research
Jun 10, 2019 06:46 AM
SYNG Pharmaceuticals Inc.
Syng Pharmaceuticals Inc. - Company Report
Reports
10
Infinata, Inc.
Infinata Research
Mar 11, 2019 04:50 AM
SYNG Pharmaceuticals Inc.
Syng Pharmaceuticals Inc. - Company Report
Reports
9
Infinata, Inc.
Infinata Research
Dec 31, 2018 04:15 AM
SYNG Pharmaceuticals Inc.
Syng Pharmaceuticals Inc. - Company Report
Reports
7
Infinata, Inc.
Infinata Research
Sep 24, 2018 04:59 AM
SYNG Pharmaceuticals Inc.
Syng Pharmaceuticals Inc. - Company Report
Reports
7


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Key Board Members Details
Name
Title
Phone
Fax
Email
Casper, Robert F.
Chair of Clinical Advisory Board
613-532-9426
-

Tataryn, Ivanna 
Member of Clinical Advisory Board
613-532-9426
-

Young, Steven 
Member of Clinical Advisory Board
613-532-9426
-

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Singh, Vinay 
Founder & CEO
613-532-9426
-

Hsu, Ted 
Communications Director
613-532-9426
-

Singh, Avinash 
COO of India
613-532-9426
-

* denotes that the relationship is proprietary

S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
